Drug Type Small molecule drug |
Synonyms (±)-doxapram, 1-ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone, Doxapram + [9] |
Target- |
Mechanism Central nervous system stimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (23 Jun 1965), |
Regulation- |
Molecular FormulaC24H33ClN2O3 |
InChIKeyZOMBFZRWMLIDPX-UHFFFAOYSA-N |
CAS Registry7081-53-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01872 | Doxapram Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Respiratory Insufficiency | CN | 01 Jan 1991 | |
Respiratory Insufficiency | CN | 01 Jan 1991 | |
Apnea | JP | 14 Feb 1976 | |
Lung Diseases | US | 23 Jun 1965 |
Not Applicable | - | - | waiefdcuqf(cioxkplqmf) = oqdnavkstq iqbyahadvp (lyfdrjzpkj ) View more | - | 27 Aug 2022 | ||
Ketodoxapram | waiefdcuqf(cioxkplqmf) = flpymgllhz iqbyahadvp (lyfdrjzpkj ) View more | ||||||
Not Applicable | - | rcijruwnpt(phnimlsesf) = tutgthkheg unleswoopo (zbotxhfejm ) | - | 01 Sep 2019 | |||
Phase 4 | Apnea Third line | 85 | Doxapram dosing adjusted for gender and postmenstrual age (GrA) | fcfgzvmlrq(xegkvsoumz) = ovjbjghkia qvoiastctp (ztitujnegr ) | - | 01 Dec 2016 | |
(Infants' weight alone (GrW)) | fcfgzvmlrq(xegkvsoumz) = laeeiwirgr qvoiastctp (ztitujnegr ) |